Recently, China Healthcare Innovation Platform (CHIP) released the 2023 Chipe Seed Series List. Unknown-kun obtained"2023 Qipu Seeds Future Star".Prize.
It is reported that the China Health Industry Innovation Platform was launched in 2014, mainly focusing on local business model innovation, management innovation, institutional innovation, and major technological innovation, aiming to enhance the positive value and social cognition of innovation by connecting industry, academia, and investment, improve and enhance the interests of stakeholders and the whole society, and then obtain good economic and social benefits, lead the value innovation atmosphere of the health industry, and promote the healthy development of the health industry in the new medical reform environment.
The Chipple Seed List encourages early-stage project innovation, "makes innovation visible", and explores potential projects that are expected to become the future of ChippleThe joint release of the list includes Shanghai Minhang Chunshen Pyramid Talent College, Shanghai Nan Science and Technology Innovation Training Base, Shanghai Wujiaochang Innovation and Entrepreneurship College, New Shanghai Business, China Pharmaceutical Industry Information Center, Beijing Medical Robot Industry Entrepreneurship Center, Shanghai Free Trade No. 1 Life Science and Technology Park, Shanghai Fenglin Juke, Takeda China, Guangzhou Jiutai Pharmaceutical and Medical Device Technology *** Aoshida Medical Device Industry Group, Rui Zhengfu, Jian Yi Capital, Warburg Pincus, Eli Lilly Asia**, Entrepreneurship Relay, Haoyue Capital, Probe Capital, Shengshi Consulting, China Innovation and Entrepreneurship Competition, Yiduo Technology, Shell Society, Kaisi Club, Sina Health, China Enterprise Video, Yunque Medical, No. 1 Medical Channel, Medical Circle, Medical Circle, Medical Circle, etc.
In this year's selection, Unknown Jun was invited to participate. Unknown Jun has established a highly independent AI microbiome research and industrial transformation platform to open up the transformation link from "data" to "drug + product".The company has carried out business and product layout in three directions: drug discovery, intestinal bacteria transplantation and probiotics, and has four pipelines entering the clinical stage, and two have recently entered the clinical phase II stage.
At the same time, Unknown Jun actively expands the transformation of FMT intestinal bacteria transplantation technology. The company has developed an AI-FMT intestinal bacteria transplantation solution to empower hospitals and health institutions to provide deep learning-based donor-patient matching, customized transplantation strategies, multi-dimensional effect evaluation, and precise probiotic nutrition intervention programs, bringing clinical benefits to hundreds of millions of patients with chronic diseases and sub-healthy people.
In the field of probiotics, the company has completed business cooperation and transformation with many domestic and international leading health companies, signed a business cooperation of 10 million yuan, and continued to promote the development of strains with independent property rights. With the above achievements, Unknown Jun won the "Qipu Seed Future Star" award, and at the event site, Professor Cai Jiangnan, the chief architect of Qipu, awarded certificates to Unknown Jun and other future star projects.
end-